A Pilot Study of Bortezomib/Dexamethasone Followed by Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone for the Initial Treatment of MIDD Associated with Multiple Myeloma and Amyloidosis

Protocol
11-061
Full Title
Pilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Phase
Pilot
Disease Status
Newly Diagnosed
Purpose

Monoclonal immunoglobulin deposition disease (MIDD — also known as Light Chain Deposition Disease, or LCDD) and amyloidosis are two rare conditions associated with abnormal plasma cells. The purpose of this study is to evaluate a treatment regimen that consists of the drugs bortezomib and dexamethasone, followed by a transplant of a patient’s own stem cells (autologous stem cell transplantation), and then another round of bortezomib and dexamethasone as maintenance therapy in patients with MIDD or amyloidosis.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have MIDD/LCDD or amyloidosis.
  • Patients may not have already been treated for the disease, with the exception of one cycle of dexamethasone.
  • Patients may not have had prior treatment with bortezomib.
  • At least 3 weeks must have passed since completion of any prior radiation therapy.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.

Disease(s)
Hematology: Hematologic Disorders
Hematology: Hematologic Malignancies
Hematology: Multiple Myeloma
Related Diseases